iPill offering is now closed and is no longer accepting investments.

Remote Monitoring Technology to Combat the Opioid Crisis


iPill is a pill dispenser with a smartphone application, designed to directly address and combat the opioid crisis.
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.


Reasons Icon

iPill has won numerous competitions, has been designated by the FDA as a “breakthrough” medical device, and received FDA Class I Registration.

Reasons Icon

iPill’s serviceable addressable market is $10 billion annually.

Reasons Icon

iPill has been granted 3 patents and is the only pill dispenser on the market that is completely tamper-resistant and has insurance coverage.


17532 Marengo Dr
Rowland Heights, CA 91748

iPill is a pill dispenser with a smartphone application, designed to directly address and combat the opioid crisis.


John Hsu MD
John Hsu MD
CEO & Co-Founder

Dr. Hsu, has practiced anesthesia and pain management for 28 years. Combining his knowledge of anesthesia, software and hardware, his latest innovation is using remote monitoring technology to ensure opioid prescription adherence to reduce opioid abuse and diversion. His company, iPill dispenser has 3 granted patents to fight the opioid epidemic and is FDA registered. Another company, he founded, Quivivepharma is concerned with drug development. It is combining oral opioids with an oral respiratory stimulant to counteract opioid induced respiratory respiratory depression. It is fast-tracked by the FDA and has 2 granted patents. He is devoted to making a social impact with projects that can save lives, improve healthcare, and reduce medical expenses.

Sherie Hsieh, BS
Sherie Hsieh, BS
COO, Director & Co-Founder

Ms. Hsieh, a clinical toxicologist and Co-Founder of the iPill. She handles daily activities of the iPill. She has experience as director of marketing at Quivivepharma and was responsible for brand awareness and business development. Ms. Hsieh, leads her own private investment company.


May 22, 2021
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares



iPill inc

Corporate Address


17532 Marengo Dr, Rowland Heights, CA 91748

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



COVID Relief

This offering is being conducted on an expedited basis due to circumstances relating to COVID-19 and pursuant to the SEC’s temporary COVID-19 regulatory relief set out in Regulation Crowdfunding §227.201(z).

Expedited closing sooner than 21 days.

Further, in reliance on Regulation Crowdfunding §227.303(g)(2) A funding portal that is an intermediary in a transaction involving the offer or sale of securities initiated beginning May 4, 2020 in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) by an issuer that is conducting an offering on an expedited basis due to circumstances relating to COVID-19 shall not be required to comply with the requirement in paragraph (e)(3)(i) of this section that a funding portal not direct a transmission of funds earlier than 21 days after the date on which the intermediary makes publicly available on its platform the information required to be provided by the issuer under §§227.201 and 227.203(a).

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Early Bird

Friends and Family - First 6 days | 5% bonus shares

Early Bird Bonus - Next 7 days | 4% bonus shares


* Tier 1 perk - ($5,000+ 1% bonus shares)

* Tier 2 perk - ($10,000 + 2% bonus shares)

* Tier 3 perk - ($25,000+ 3% bonus shares)

* Tier 4 perk - ($50,000+ 5% bonus shares)

*All perks occur when the offering is completed.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.



Drug Expert: U.S. Needs an 'Operation Warp Speed' for Opioid Epidemic

The opioid crisis is 20 years old.  Why do we continue to repeat the same thing over and over again and expect a different result?  Instead of treating the symptoms which prolongs disease and offers no cure.  iPill is on a different path.

iPill is in the final stages of planning our human factor trials at an OUD treatment center Aspire365 to collect data on feasibility, usability, and acceptance.  We have spoken to Ohio Governor Mike DeWine's office about collaborating on the study because Ohio has one of the highest opioid overdose death rate in the country.   We hope this leads to an introduction to Sen. Rob Portman, (R-OH), Author, Comprehensive Addiction and Recovery Act (CARA) and CARA 2.0 and potential Federal support for the iPill initiative.

With State and Federal support, and the support of the DEA (a called is planned next week), it is our hope to change the standard of care.  The same opioid triple locked in hospitals, will be given the same safety protocols in patients homes.  Secure storage, active control dispensing, and destruction of unused opioids on tampering and prescription end.


I have hope today with two bright spots

NSF & NIDA/NIH/HEAL initiative Grant submission

For the past 22 years I have been combating opioid over usage in my medical practice.  I was harshly criticized for adopting multimodal pain therapy just as “pain” was becoming the “5th vital sign” and the opioid crisis was beginning.  Multimodal pain therapy is now used as a measure of the quality of anesthesia and determine physician reimbursement.  My actions were 22 years too early.

Today I have hope.  

I hope that with the changing attitude towards prevention of OUD,  the iPill will be funded by a grant.  In trying to get an update for the grant applications submitted to the National Science Foundation (NSF) for $256,000 and to the NIDA/NIH/HEAL Initiative SBIR Fast-Track Direct to Phase II for $2.3 million, I learned something that gave me hope.  The HHS Secretary announced that  prevention was the next frontier in opioid use disorder (OUD) because treatment is relapse rates and the costs are astronomical.  The Surgeon general made the same assessment.

I have hope in a lead investor who has committed to a seed of $2 million.  In my heart I know that the iPill has the potential reduce the risk potential for OUD, save live, reduce medical costs, and improve care.

Thank you for your support


Have you locked up your opioids today?

Have you locked up your opioids today?

1 in 4 opioid overdoses now involves children and teens. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2719580

One of the biggest problems, no one really know what to do with unused pills. There are no universal recommendations for the proper disposable of unused opioids, and patients are rarely advised of what to do with unused opioids or expired medications. According to the Office of National Drug Council Policy, most medications that are no longer necessary or have expired should be removed from the containers, mixed with undesirable substances (i.e. cat litter, used coffee grounds) and put in an impermeable, nondescript container (possible container with a lid or a sealed bag) before throwing in the trash. The FDA recommends the most opioid medications, including OxyContin/acetaminophen (Percocet) and oxycodone (OxyContin tablets) and transdermal fentanyl (Duragesic transdermal system) be flush down the toilet instead of thrown in the trash. Disposal by flushing down the toilet proves immediate and definitive elimination of safety hazards from in intentional use or a accidental exposure of opioid products

Patient should be advised to flush prescription drugs down the toilet only if the label or accompanying patient information specifically instructed do so. Flashing on his medication has been the subject of controversy with some state governments and boards recommending against the practice due to pollution concerns and affects on waterways and wildlife.

The American medical Association recommends following three steps to promote the safe storage and disposal of opioids.
1. Educate patient about the safe use of opioids including not sharing prescriptions with others.
2. Remind patients that medication should be stored out of reach of children and in safe place - preferably locked to prevent other family members and visitors from taking them.
3. Talk to patients about the most appropriate way to dispose of unused expired, unwarranted, and unused medications. The preferred option is that unwanted or unused pills, liquid or other medication should be disposed of in a local “take back” or mail back program or medication dropbox at a police station, pharmacy, or unauthorized collection site. Contact your state law enforcement agency or visit HTTPS://takeback-day.DEA.GOV to determine if a program is in your area


A new use for the iPill, a new market segment

Recently, we were contacted by a company that treats depression with Ketamine.  They expressed interest in using iPill to save delivery costs and ensure medication adherence and reduce abuse.  The company currently overnight delivers a single dose of medications to the patient’s home and videoconference ingestion.  Their daily delivery costs are over $120 and see using the iPill to realize a 75% reduction in transportation expenses to $30 total. 

iPill provides secure storage, active control dispensing, and destruction of unused pills on tampering and prescription expiration.

We are demonstrating our specialized engineered solution to them tomorrow.

Once others understand the potential, we will become the new standard for delivery of medications to patients


A patient

This was a comment from the iPill website

I am having knee replacement surgery. I have been sober for 2 years and am looking for pain medication distribution options that are timed and locked: I have had issues with pain meds and alcohol. Thanks for any ideas or assistance you might have available.

My response

Thank you for the note.  Congrats on your sobriety and for reaching out.  This is impressesive because you are genuinely interested in your own well being and recovery.  

Substance use disorder (SUD) and opioid use disorder (OUD) are chronic diseases. Treatment unfortunately has focused on psychological and emotional support but leaves out the physical aspects of treatment, the pharmaceutical intervention.  You have identified the problem iPill is trying to solve. 

In hospitals, opioids are triple locked yet these same opioids are sent home with patients without similar safeguards.  Combining psychological/emotional support therapy with secure storage, active control dispensing, and destruction of unused pills on tampering and prescription end,extends the safety of opioid from the hospital to the home.

At this time iPill is not for sale to the general public.  We are conducting a feasibility, usability, and acceptance human factor study in Q3-4 2021.  We will likely be market launching shortly thereafter.

Regarding the surgery, talk to your orthopedic surgeon as soon as possible so he can contact the anesthesiologist to address your concerns.  There are predications that can be given to reduce postop pain and reduce the use of opioids.  Intraoperatively the orthopedic surgeon can inject long acting local anesthetics to the posterior capsule and the anesthesiologist can place a regional pain block (femoral + sciatic or adductor canal block).  Postop ice and a continuous passive motion (CPM) device can be used to encourage early ambulation which can improve pain and speed recovery.

The psychologic preparation for pain postop is in education.  I reassure patients that the knee replacement surgeries enable return to better function in the long run.  There will be pain, and possibly lots of pain.  It willl be for a short period of time for long term gain. Patients sometimes tell me that with this uderstanding, they were better able to tolerate the postop pain knowing what to expect preoperatively.

Again postoperatively it will hurt.   Early ambulation will reduce pain. Adhering to the physicial therapy regimen will not only reduce pain but improve range of motion to ensure a successful surgical outcome.  Elevation of the operative side combined with an activity to distract from the pain is extremely important emotionally. Watching movies is a great alternative.   Good nutrition is very important for healing. Good luck

Thank you 

John Hsu MD


The need for the iPill continues to grow

The need for the iPill continues to grow. Drug overdose deaths have surged during the Covid-19 pandemic, with provisional CDC data predicting over 88,000 overdose deaths from September 2019 through August 2020, a 27 percent increase from the prior 12-month period. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#dashboard

FDA approves higher dose naloxone nasal spray for treating opioid overdose.https://www.healio.com/news/psychiatry/20210430/fda-approves-higher-dose-naloxone-nasal-spray-for-treating-opioid-overdose

The opioid overdose is over 20 years old and if we continue to treat the symptoms and not one of the causes more people will continue to dies

"We lost 88,000 people in the 12-month period ending in August 2020," Regina LaBelle told reporters during a morning briefing. "Illicitly manufactured fentanyl and synthetic opioids are the primary drivers of this increase."

We must not forget the 41 people who die a day from prescription opioid overdoses. https://www.cdc.gov/drugoverdose/data/analysis.html

86% of Heroin addicts report 1st abusing prescription opioids as teens. https://www.drugabuse.gov/publications/research-reports/relationship-between-prescription-drug-heroin-abuse/prescription-opioid-use-risk-factor-heroin-use.

iPill is trying to reduce the risk of misuse.

if you don't believe me please see this message that was emailed to me:

I am having knee replacement surgery. I have been sober for 2 years and am looking for pain medication distribution options that are timed and locked: I have had issues with pain meds and alcohol. Thanks for any ideas or assistance you might have available.


Can the DEA mandate the iPill like the child resistant cap from 1967

We have reached out to the DEA and have a call next week to present the iPill.

9.8 million opioid units lost 2018and 6.8 million units lost 2019. https://www.dea.gov/sites/default/files/2018-11/DIR-032-18%202018%20NDTA%20final%20low%20resolution.pdf

iPill destroys unused pills after the prescription term ends so they can't be accidentally ingested or stolen.


Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the iPill offering. Here's an excerpt describing the specifics of the change:

iPill has extended their campaign and updated their financials

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into iPill.


Tier 1 perk

$5,000+ 1% bonus shares


Tier 2 perk

$10,000 + 2% bonus shares)


Tier 3 perk

$25,000+ 3% bonus shares)


Tier 4 perk

$50,000+ 5% bonus shares)




Cancel anytime before 48 hours before a rolling close or the offering end date.


REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team


Important Message


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.